Exosome Diagnostics and MD Anderson Cancer Center Demonstrate Superior Liquid Biopsy Performance of Exosome Diagnostics’ ExoLution® Plus Platform That Simultaneously Analyzes Exosomal Nucleic Acids and Cell-Free DNA

In a November 13, 2017 press release, it was announced that Exosome Diagnostics, Inc., and MD Anderson Cancer Center had a unique study published online on October 19, 2017 in Clinical Cancer Research, a peer-reviewed publication of the American Association of Clinical Cancer Research. The analysis directly compared Exosome Diagnostics’ ExoLution® Plus platform with two different platforms, BEAMing and ddPCR, that analyze cell-free (cf) DNA alone. The article is titled “Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA compared with Clinical Outcomes of Patients with Advanced Cancers.” Teams at MD Anderson Cancer Center and Exosome Diagnostics showed that the ExoLution Plus platform, which simultaneously analyses exosome nucleic acids (exoNA) and cfDNA correlated better to clinical outcome than cfDNA analysis alone in a cohort of 43 patients with progressive advanced cancer. The teams studied overall survival among the patients and linked low amounts of mutated exoNA with longer survival times and high amounts of mutated exoNA with shorter survival times. "Our study reports two novel observations. First, our data suggest that next-generation sequencing of plasma-derived exosomal nucleic acids from patients with advanced cancers has high sensitivity compared to molecular testing of plasma cell-free DNA or archival tumor samples. Second, we demonstrated that the amount of mutated exosomal nucleic acids is an independent prognostic factor for survival" said Dr. Filip Janku, MD Anderson Cancer Center senior author on the study.
Login Or Register To Read Full Story